SecurityCMPGY / Compass Group Plc (20449X302)
Institutional Owners18
Institutional Shares2,989,619
Institutional Value$ 1,224,803,000 USD

Institutional Stock Ownership and Shareholders()

CMPGY / Compass Group Plc Institutional Ownership

Compass Group Plc (OTC:CMPGY) has 18 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,989,619 shares. Largest shareholders include Parametric Portfolio Associates Llc, Aristotle Capital Management, LLC, Silvercrest Asset Management Group Llc, Scout Investments, Inc., World Asset Management Inc, Geneva Advisors, LLC, Paradigm Asset Management Co Llc, Northroad Capital Management Llc, Hartwell J M Limited Partnership, and Quadrant Capital Group Llc.
Compass Group Plc (OTC:CMPGY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="CMPGY / Compass Group Plc Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 7,785 7,401 -4.93 168 151 -10.12
2018-05-02 13F-HR FTB Advisors, Inc. 359 359 0.00 7 7 0.00
2018-05-10 13F-HR QUADRANT CAPITAL GROUP LLC 2,970 7,438 150.44 57 146 156.14
2018-05-15 13F-HR GLENMEDE TRUST CO NA 2,972 2,972 0.00 64 64 0.00
2018-05-16 13F-HR Private Capital Group, Llc 3 2,327 77,466.67 51 48 -5.88
2018-05-15 13F-HR Aristotle Capital Management, LLC 723,423 730,240 0.94 15,657 14,910 -4.77
2018-07-11 13F-HR Vigilant Capital Management, LLC 981 21
2018-05-15 13F-HR SILVERCREST ASSET MANAGEMENT GROUP LLC 145,634 151,589 4.09 3,197 3,158 -1.22
2018-07-16 13F-HR SCOUT INVESTMENTS, INC. 154,172 146,944 -4.69 3,148 3,140 -0.25
2018-05-21 13F-HR Mcilrath & Eck, Llc 45 0 -100.00 1 0 -100.00
2018-05-07 13F-HR PARADIGM ASSET MANAGEMENT CO LLC 56,937 1,162,526
2018-04-12 13F-HR OREGON PUBLIC EMPLOYEES RETIREMENT FUND 638,250 0 -100.00 13,814 0 -100.00
2018-07-16 13F-HR Lenox Wealth Advisors, Inc. 0 404 0 9
2018-04-23 13F-HR World Asset Management Inc 89,390 62,999 -29.52 1,935 1,313 -32.14
2018-05-11 13F-HR Gemmer Asset Management LLC 99 2
2017-08-07 13F-HR Geneva Advisors, LLC 60,200 59,879 -0.53 1,136 1,264 11.27
2018-07-13 13F-HR HARTWELL J M LIMITED PARTNERSHIP 21,784 21,784 0.00 454 472 3.96
2016-11-14 13F-HR NORTHROAD CAPITAL MANAGEMENT LLC 193,086 56,856 -70.55 3,688 1,104 -70.07
2018-04-18 13F-HR Sonora Investment Management, LLC 70 70 0.00 1,537 1,458 -5.14
2018-05-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 1,557,458 1,680,340 7.89 34,194 35,010 2.39

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

4h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

5h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

European shares retreat as trade worries weigh on tech

2018-07-04 reuters
LONDON (Reuters) - European shares slipped on Wednesday as worries over global trade persisted, with sentiment souring around semiconductor stocks in particular after U.S. peer Micron was banned from selling chips in China. (3-0)

UPDATE 1-UK Stocks-Factors to watch on June 21

2018-06-21 reuters
June 21 (Reuters) - Britain’s FTSE 100 index is seen opening 49 points higher at 7,676 on Thursday, according to financial bookmakers, with futures up 0.28 percent ahead of the cash market open. (37-0)

UK companies said to face pre-Brexit tax bombshell from EU

2018-06-20 malaymail
LONDON, June 20 — The European Union is on course to hand dozens of UK-based companies a pre-Brexit tax bombshell, according to people familiar with a state-aid probe that could lead to bills exceeding £1 billion (RM5.2 billion.) (160-0)

Unwise To Go Long WisdomTree At Present Valuation Level

2018-05-17 seekingalpha
WisdomTree Investments Inc. operates as an ETF sponsor and asset manager. The company offers Equity ETFs, International Hedged Equity ETFs, Currency ETFs, Commodities ETFs and Fixed Income ETFs. It is the ninth largest ETF sponsor globally with AUM of ~$65 billion. (20-0)

Compass Group's (CMPGF) CEO Dominic Blakemore on Q2 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Compass Group Plc (OTCPK:CMPGF) Q2 2018 Results Earnings Conference Call May 9, 2018 4:00 AM ET (1-0)

CUSIP: 20449X302